Labiotech.eu

Eli Lilly Topas Therapeutics Autoimmune Disease

News and Trends 22 Aug 2017

Eli Lilly Partners with German Biotech Against Autoimmune Disease

Topas Therapeutics has signed a multi-year agreement with Eli Lilly to develop drug candidates for antigen-specific immunotherapy. The young Topas Therapeutics, a spin off from Evotec launched just last year, has managed to sign a research collaboration deal with big pharma Eli Lilly. The partners will work together on selecting external antigens that induce inflammation and autoimmune disease […]

August 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Aug 2017

First-in-Human Trial will test a New Cancer Therapy from Switzerland

Cellestia Biotech will start human trials with CB-103, an anticancer drug targeting the Notch signaling pathway, known for its ubiquity in cancer. Cellestia Biotech, based in Basel, has announced it received full approval to start clinical trials in Spain with CB-103, a new class of drug that targets an ubiquitous cancer mechanism. The drug is a […]

August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Immatics cancer personalized cell therapy

News and Trends 21 Aug 2017

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with the potential to treat multiple types of solid tumors. Based in Tübingen, Germany, Immatics has announced today the start of its first clinical trial testing its cell therapy technology aimed at providing personalized treatments for multiple types of solid tumors. The […]

August 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Astrazeneca Ethris mRNA Therapy MedImmune Edited

News and Trends 21 Aug 2017

AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy

AstraZeneca and its R&D arm MedImmune have partnered with Munich-based Ethris to use its mRNA technology to develop treatments for respiratory disease. Ethris, located in the Munich biotech hub of Martinsried, has attracted the attention of AstraZeneca with its mRNA platform despite still being in an early development stage. The big pharma will pay Ethris €25M […]

August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Novo Nordisk Semaglutide GLP 1 receptor agonist type 2 diabetes Eli Lilly Trulicity dulaglutide

More News! 18 Aug 2017

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisk’s semaglutide with Eli Lilly’s Trulicity (dulaglutide), already in the market, have revealed that Novo’s […]

August 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 18 Aug 2017

Swedish Scientists Launch Online Pathology Atlas of All Known Cancer Genes

A team of Swedish researchers has published today an interactive map for the visualization of the effects of individual cancer genes that supports personalized medicine. The new Pathology Atlas is an open access online resource containing genomic data from over 8,000 patients across 17 major cancer types. By typing in the name of any gene […]

August 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biosimilars market novartis sandoz roche boehringer ingelheim

News and Trends 16 Aug 2017

Biosimilars Struggle to Substitute Brand-Name Drugs

Despite bringing a significant price reduction, biosimilars might lag in taking over the market of the drugs they copy because of exclusivity policies set up by the owners of brand-name drugs. A report in Bloomberg Markets yesterday highlights the case of Inflectra, a biosimilar from Pfizer that imitates Johnson & Johnson’s rheumatoid arthritis blockbuster Remicade (infliximab). Despite bringing a price reduction […]

August 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Aug 2017

And the Winner for the BioPharm America 2017 FREE Ticket Giveaway is…

Three weeks ago, on July 26th, we published the free ticket giveaway for the BioPharm America conference in Boston, Massachusetts, which is taking place from September 26th – 27th, 2017! Today, our randomizer selected Susanna Bächle from Addgene as the WINNER! Congratulations! Susanna was selected randomly from a long list of entries, so thank you to […]

August 16, 2017 - 3 minutesmins - By External Contributor

Mundipharma CellAct Biliary Tract Cancer

News and Trends 14 Aug 2017

UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer

Mundipharma has acquired the rights to CAP7.1, a drug that could bring the first alternative to surgery and chemo for patients with biliary tract cancer. Cambridge-based Mundipharma has paid $250M (€212M) to the German biotech CellAct in exchange for the worldwide development, commercialization and manufacturing rights to CAP7.1. The candidate is a prodrug that, when metabolized, […]

August 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biotecnol cancer research uk immuno oncology

News and Trends 11 Aug 2017

Cancer Research UK Teams Up with London Startup in Immuno-oncology

Biotecnol, based in London, has found a partner in CRUK to bring its immune-stimulating antibody into the clinic to tackle solid tumors. There will (probably) be a new immuno-oncology drug on the block soon: Cancer Research UK has gone in on London startup Biotecnol‘s antibody in a deal to bring it to an open-label Phase […]

August 11, 2017 - 1 minutemin - By Evelyn Warner

galapagos glpg1690 idiopathic pulmonary fibrosis

More News! 10 Aug 2017

Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market

Galapagos’ GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a win in Phase IIa for its candidate GLPG1690, which aims to treat patients with idiopathic pulmonary fibrosis (IPF). The median survival is 2 to 5 years after […]

August 10, 2017 - 2 minutesmins - By Evelyn Warner

More News! 9 Aug 2017

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory epilepsy with focal seizures had not met any of its endpoints in a Phase II […]

August 9, 2017 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eli Lilly Partners with German Biotech Against Autoimmune Disease

First-in-Human Trial will test a New Cancer Therapy from Switzerland

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

Swedish Scientists Launch Online Pathology Atlas of All Known Cancer Genes

Biosimilars Struggle to Substitute Brand-Name Drugs

And the Winner for the BioPharm America 2017 FREE Ticket Giveaway is…

UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer

Cancer Research UK Teams Up with London Startup in Immuno-oncology

Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!